Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 24Terminated 9Unknown 7Recruiting 5Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Breast Neoplasms 9Endometrial Neoplasms 4Carcinoma, Renal Cell 4Neuroendocrine Tumors 3Tuberous Sclerosis 2Recurrence 2Neoplasm Metastasis 2Kidney Neoplasms 2Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Diseases 1Solid Tumor 1Seizures 1Sarcoma 1Primary Non-metastatic Breast Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Endocrine Neoplasia Type 1 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Hyperplasia 1Clear-cell metastatic renal cell carcinoma 1Breast Neoplasms, Male 1Angiomyolipoma 1Advanced Solid Tumors 1Advanced Cancer 1

Interventions

pembrolizumab 34Specimen Handling 18Paclitaxel 16Magnetic Resonance Spectroscopy 15Carboplatin 14Biopsy 14Nivolumab 13Ipilimumab 12Gemcitabine 10Irinotecan 9Radiosurgery 8atezolizumab 7abemaciclib 7Radiation 7Pemetrexed 7Cisplatin 7Capecitabine 7130-nm albumin-bound paclitaxel 7trastuzumab deruxtecan 6olaparib 6durvalumab 6avelumab 6Docetaxel 6osimertinib 5adagrasib 5Trastuzumab 5Fulvestrant 5Cetuximab 5Albumin-Bound Paclitaxel 5palbociclib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasm Metastasis × Everolimus × Clear all
NCT02321501 2026-05-20

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
37 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03065387 2026-01-12

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
93 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡